Gestational diabetes and other adverse pregnancy outcomes in polycystic ovary syndrome.

IF 2.6 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2022-12-01 Epub Date: 2022-08-19 DOI:10.1097/MED.0000000000000769

Daryl J Selen, Camille E Powe

{"title":"Gestational diabetes and other adverse pregnancy outcomes in polycystic ovary syndrome.","authors":"Daryl J Selen, Camille E Powe","doi":"10.1097/MED.0000000000000769","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review provides an update on gestational diabetes (GDM) and other adverse pregnancy outcomes in individuals with polycystic ovary syndrome (PCOS), one of the most common metabolic disorders and causes of infertility.Recent findings: Recent studies using Rotterdam diagnostic criteria for PCOS have supported prior literature suggesting that pregnant individuals with PCOS are at an increased risk of GDM. Risk factors for GDM in this population include overweight/obesity, insulin resistance, hyperandrogenism, amenorrhea, and history of miscarriage. It is possible that subtypes of PCOS (metabolic vs. lean/reproductive) pose differential risk. There are no current screening or treatment guidelines specifically for individuals with PCOS for GDM prevention. Although metformin has been studied for GDM prevention in PCOS, there has been no proven benefit. For infertility treatment, assisted reproductive technology and in-vitro fertilization do not appear to increase the risk of GDM in individuals with PCOS desiring pregnancy.Summary: Recent studies of pregnant individuals with PCOS suggest an increased risk of adverse pregnancy outcomes, including GDM. Larger, prospective studies using standardized diagnostic criteria are warranted to determine if the risk is from PCOS generally, or if there are subtypes of PCOS (metabolic vs. lean/reproductive) at a higher risk of GDM than others.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"29 6","pages":"521-527"},"PeriodicalIF":2.6000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613547/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Endocrinology & Diabetes and Obesity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MED.0000000000000769","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose of review: This review provides an update on gestational diabetes (GDM) and other adverse pregnancy outcomes in individuals with polycystic ovary syndrome (PCOS), one of the most common metabolic disorders and causes of infertility.

Recent findings: Recent studies using Rotterdam diagnostic criteria for PCOS have supported prior literature suggesting that pregnant individuals with PCOS are at an increased risk of GDM. Risk factors for GDM in this population include overweight/obesity, insulin resistance, hyperandrogenism, amenorrhea, and history of miscarriage. It is possible that subtypes of PCOS (metabolic vs. lean/reproductive) pose differential risk. There are no current screening or treatment guidelines specifically for individuals with PCOS for GDM prevention. Although metformin has been studied for GDM prevention in PCOS, there has been no proven benefit. For infertility treatment, assisted reproductive technology and in-vitro fertilization do not appear to increase the risk of GDM in individuals with PCOS desiring pregnancy.

Summary: Recent studies of pregnant individuals with PCOS suggest an increased risk of adverse pregnancy outcomes, including GDM. Larger, prospective studies using standardized diagnostic criteria are warranted to determine if the risk is from PCOS generally, or if there are subtypes of PCOS (metabolic vs. lean/reproductive) at a higher risk of GDM than others.

查看原文本刊更多论文

多囊卵巢综合征的妊娠期糖尿病和其他不良妊娠结局。

综述目的:本综述提供了妊娠糖尿病(GDM)和多囊卵巢综合征(PCOS)患者的其他不良妊娠结局的最新进展，多囊卵巢综合征是最常见的代谢疾病之一，也是导致不孕的原因。最近的研究结果:最近的研究使用鹿特丹诊断多囊卵巢综合征的标准支持先前的文献，表明怀孕的多囊卵巢综合征患者患GDM的风险增加。该人群中发生GDM的危险因素包括超重/肥胖、胰岛素抵抗、高雄激素、闭经和流产史。多囊卵巢综合征的亚型(代谢性与瘦弱/生殖性)可能会造成不同的风险。目前还没有专门针对多囊卵巢综合征患者预防GDM的筛查或治疗指南。虽然二甲双胍已被研究用于预防多囊卵巢综合征的GDM，但尚未证实其有益。对于不孕症治疗，辅助生殖技术和体外受精似乎不会增加希望怀孕的PCOS患者发生GDM的风险。摘要:最近对多囊卵巢综合征孕妇的研究表明，包括GDM在内的不良妊娠结局的风险增加。使用标准化诊断标准的更大规模的前瞻性研究是有必要的，以确定风险是否来自一般的多囊卵巢综合征，或者是否有多囊卵巢综合征亚型(代谢性与瘦弱/生殖性)比其他亚型更容易发生GDM。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Endocrinology & Diabetes and Obesity ENDOCRINOLOGY & METABOLISM-

CiteScore

5.80

自引率

3.10%

发文量

128

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Endocrinology, Diabetes and Obesity delivers a broad-based perspective on the most recent and exciting developments in the field from across the world. Published bimonthly and featuring twelve key topics – including androgens, gastrointestinal hormones, diabetes and the endocrine pancreas, and neuroendocrinology – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.